Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 4/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | GFER | P55789 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494087 | 0.83 | P2RX3 (0.47) | P2RX3P2RX2 | |
| SCHEMBL5532289 | 0.81 | POLB (0.42) | LMNAPOLBGAAGFERALDH1A1 | |
| SCHEMBL20177154 | 0.81 | ADRA1A (0.38) | LMNAPOLBGAAGFERALDH1A1 | |
| SCHEMBL14599985 | 0.78 | P2RX3 (0.46) | LMNAPOLBGAAGFERALDH1A1 | |
| SCHEMBL22448701 | 0.76 | POLB (0.33) | POLBGAAALDH1A1ALOX15HTT | |
| SCHEMBL19364184 | 0.76 | P2RX3 (0.42) | LMNAPOLBGAAGFERALDH1A1 | |
| SCHEMBL28767120 | 0.75 | LMNA (0.57) | LMNAPOLBGAAGFERALDH1A1 | |
| SCHEMBL25484238 | 0.74 | ALDH1A1 (0.50) | ALDH1A1MAPTSMN1; SMN2KDM4EL3MBTL1 | |
| SCHEMBL18959730 | 0.74 | ALDH1A1 (0.40) | LMNAPOLBGAAALDH1A1MAPT | |
| SCHEMBL2485209 | 0.74 | P2RX3 (0.50) | LMNACYP1A2CYP2D6HTR2CP2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180141919-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2018-05-24 | — | — | US | disclosed |
| US-20170326142-A1 | SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH | Afferent Pharmaceuticals. Inc. (US) | 2017-11-16 | — | — | US | disclosed |
| US-9724346-B2 | Substituted pyrimidines for treatment of a cough selected from chronic pathological cough, sub-acute pathological cough, acute pathological cough, neuronal hypersensitivity underlying chronic cough, neuronal hypersensitivity underlying sub-acute cough and neuronal hypersensitivity underlying acute cough | AFFERENT PHARMACEUTICALS INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170151241-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | AFFERENT PHARMACEUTICALS INC. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170096404-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2017-04-06 | — | — | US | disclosed |
| US-9556127-B2 | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160271131-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160263112-A1 | SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH | Afferent Pharmaceuticals, Inc. (US) | 2016-09-15 | — | — | US | disclosed |
| US-9284279-B2 | Substituted pyrimidines for treatment of acute cough, chronic cough and urge to cough | Afferent Pharmaceuticals, Inc. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150057299-A1 | Methods of Using Diaminopyrimidine P2X3 and P2X 2/3 Receptor Modulators for Treatment of Acute and Sub-Acute Cough, Urge to Cough and Chronic Cough, in Respiratory Diseases | Afferent Pharmaceuticals, Inc. | 2015-02-26 | — | — | US | disclosed |
| US-20140357629-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8846705-B2 | Diaminopyrimidines as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2014-09-30 | — | — | US | disclosed |
| EP-1924264-B9 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-02-19 | — | — | EP | disclosed |
| EP-1924264-B1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-8524725-B2 | Methods of using diaminopyrimidine as P2X3 and P2X⅔ receptor modulators for treatment of respiratory and gastrointestinal diseases | ROCHE PALO ALTO LLC (US) | 2013-09-03 | — | — | US | disclosed |
| US-20130225570-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120122859-A1 | METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | ROCHE PALO ALTO LLC. | 2012-05-17 | — | — | US | disclosed |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | ROCHE PALO ALTO LLC | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326142-A1 | SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH | P2RX3, P2RX2, P2RX1 | LMNA 4593/4885POLB 2391/4885GAA 3704/4885 |
| US-20180141919-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | LMNA 3419/4885POLB 2392/4885GAA 2623/4885 |
| US-20170151241-A1 | METHODS AND COMPOSITIONS FOR TREATING DISEASES AND CONDITIONS | P2RX3, P2RX2, P2RX5 | LMNA 626/4885POLB 4055/4885GAA 1323/4885 |
| US-20110077242-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | LMNA 3166/4885POLB 2735/4885GAA 2503/4885 |
| US-20150057299-A1 | Methods of Using Diaminopyrimidine P2X3 and P2X 2/3 Receptor Modulators for Treatment of Acute and Sub-Acute Cough, Urge to Cough and Chronic Cough, in Respiratory Diseases | P2RX3, P2RX2, P2RX5 | LMNA 4682/4885POLB 3763/4885GAA 4287/4885 |
| US-20120122859-A1 | METHODS OF USING DIAMINOPYRIMIDINE AS P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX6 | LMNA 4095/4885POLB 2698/4885GAA 3192/4885 |
| US-20170096404-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | LMNA 3419/4885POLB 2392/4885GAA 2623/4885 |
| US-20130225570-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | LMNA 4079/4885POLB 2957/4885GAA 3079/4885 |
| US-20160271131-A1 | METHODS OF USING DIAMINOPYRIMIDINE P2X3 AND P2X2/3 RECEPTOR MODULATORS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISEASES | P2RX3, P2RX2, P2RX1 | LMNA 4079/4885POLB 2957/4885GAA 3079/4885 |
| US-20140357629-A1 | DIAMINOPYRIMIDINES AS P2X3 AND P2X2/3 ANTAGONISTS | P2RX3, P2RX6, P2RX2 | LMNA 3166/4885POLB 2735/4885GAA 2503/4885 |
| US-20160263112-A1 | SUBSTITUTED PYRIMIDINES FOR TREATMENT OF ACUTE COUGH, CHRONIC COUGH AND URGE TO COUGH | P2RX3, P2RX2, P2RX1 | LMNA 4593/4885POLB 2391/4885GAA 3704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.